CN115192580A - 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 - Google Patents

一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 Download PDF

Info

Publication number
CN115192580A
CN115192580A CN202210356800.1A CN202210356800A CN115192580A CN 115192580 A CN115192580 A CN 115192580A CN 202210356800 A CN202210356800 A CN 202210356800A CN 115192580 A CN115192580 A CN 115192580A
Authority
CN
China
Prior art keywords
compound
erbb2
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210356800.1A
Other languages
English (en)
Chinese (zh)
Inventor
李迪
段灵峻
洪媛
张智慧
夏广新
柯樱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CN115192580A publication Critical patent/CN115192580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210356800.1A 2021-04-01 2022-03-31 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 Pending CN115192580A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021103581923 2021-04-01
CN202110358192 2021-04-01

Publications (1)

Publication Number Publication Date
CN115192580A true CN115192580A (zh) 2022-10-18

Family

ID=83458071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210356800.1A Pending CN115192580A (zh) 2021-04-01 2022-03-31 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用

Country Status (5)

Country Link
US (1) US20240197737A1 (cg-RX-API-DMAC7.html)
EP (1) EP4316491A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514098A (cg-RX-API-DMAC7.html)
CN (1) CN115192580A (cg-RX-API-DMAC7.html)
WO (1) WO2022206929A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606289A (zh) * 2022-02-17 2023-08-18 上海医药集团股份有限公司 一种含氮杂环化合物的晶型、制备方法及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
AU2024255740A1 (en) * 2023-04-11 2025-10-23 Cogent Biosciences, Inc. Erbb2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101219102A (zh) * 2007-12-11 2008-07-16 山东蓝金生物工程有限公司 一种治疗实体肿瘤的拉帕替尼缓释植入剂
CN102731395A (zh) * 2011-04-15 2012-10-17 中国科学院上海药物研究所 抗肿瘤药物来那替尼的中间体及其制备与应用
CN109422755A (zh) * 2017-09-01 2019-03-05 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
CN115057861A (zh) 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
MX2023003362A (es) * 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2023155899A1 (zh) * 2022-02-17 2023-08-24 上海医药集团股份有限公司 一种含氮杂环化合物的晶型、制备方法及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101219102A (zh) * 2007-12-11 2008-07-16 山东蓝金生物工程有限公司 一种治疗实体肿瘤的拉帕替尼缓释植入剂
CN102731395A (zh) * 2011-04-15 2012-10-17 中国科学院上海药物研究所 抗肿瘤药物来那替尼的中间体及其制备与应用
CN109422755A (zh) * 2017-09-01 2019-03-05 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHONGBEN TANG,等: "Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma", FRONT ONCOL, vol. 11, 18 March 2021 (2021-03-18), pages 605658 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606289A (zh) * 2022-02-17 2023-08-18 上海医药集团股份有限公司 一种含氮杂环化合物的晶型、制备方法及应用
CN116606289B (zh) * 2022-02-17 2026-02-24 上海医药集团股份有限公司 一种含氮杂环化合物的晶型、制备方法及应用

Also Published As

Publication number Publication date
US20240197737A1 (en) 2024-06-20
EP4316491A1 (en) 2024-02-07
JP2024514098A (ja) 2024-03-28
WO2022206929A1 (zh) 2022-10-06
EP4316491A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
CN108137593B (zh) 蛋白激酶抑制剂的制备和用途
JP6732906B2 (ja) ピリミジン誘導体及びその使用
TW202136252A (zh) 化合物及其用途
US20180325901A1 (en) Chiral diaryl macrocycles and uses thereof
WO2022206929A1 (zh) 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用
JP2010505859A (ja) タンパク質キナーゼ阻害剤およびそれを使用するための方法
AU2021298154A1 (en) Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
EA024809B1 (ru) Замещенные соединения пиридазинкарбоксамида
EP4171556A1 (en) A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
JP2019511554A (ja) 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ
US20140350050A1 (en) Pyridine compounds as inhibitors of kinase
WO2017129094A1 (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
WO2019184966A1 (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
JP2023540491A (ja) 突然変異型egfr阻害化合物およびその適用
TW202510857A (zh) 化合物及其用途
CN115785107B (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
WO2021018017A1 (zh) 作用于egfr和erbb2的嘧啶类化合物
HK40105285A (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant
CN112279834B (zh) 一种fgfr4抑制剂、制备方法、药物组合物及其应用
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
WO2022184119A1 (zh) 酪氨酸激酶抑制剂及其药物应用
WO2017049711A1 (zh) 喹啉类衍生物、其药物组合物、制备方法及应用
CN112194652B (zh) 4-羟甲基-1h-吲哚类化合物、制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination